Cargando…

Seryl-tRNA synthetase promotes translational readthrough by mRNA binding and involvement of the selenocysteine incorporation machinery

Translational readthrough of UGA stop codons by selenocysteine-specific tRNA (tRNA(Sec)) enables the synthesis of selenoproteins. Seryl-tRNA synthetase (SerRS) charges tRNA(Sec) with serine, which is modified into selenocysteine and delivered to the ribosome by a designated elongation factor (eEFSec...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ze, Wang, Justin, Shi, Yi, Yee, Brian A, Terrey, Markus, Zhang, Qian, Lee, Jenq-Chang, Lin, Kuo-I, Wang, Andrew H-J, Ackerman, Susan L, Yeo, Gene W, Cui, Haissi, Yang, Xiang-Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602924/
https://www.ncbi.nlm.nih.gov/pubmed/37739431
http://dx.doi.org/10.1093/nar/gkad773
Descripción
Sumario:Translational readthrough of UGA stop codons by selenocysteine-specific tRNA (tRNA(Sec)) enables the synthesis of selenoproteins. Seryl-tRNA synthetase (SerRS) charges tRNA(Sec) with serine, which is modified into selenocysteine and delivered to the ribosome by a designated elongation factor (eEFSec in eukaryotes). Here we found that components of the human selenocysteine incorporation machinery (SerRS, tRNA(Sec), and eEFSec) also increased translational readthrough of non-selenocysteine genes, including VEGFA, to create C-terminally extended isoforms. SerRS recognizes target mRNAs through a stem-loop structure that resembles the variable loop of its cognate tRNAs. This function of SerRS depends on both its enzymatic activity and a vertebrate-specific domain. Through eCLIP-seq, we identified additional SerRS-interacting mRNAs as potential readthrough genes. Moreover, SerRS overexpression was sufficient to reverse premature termination caused by a pathogenic nonsense mutation. Our findings expand the repertoire of selenoprotein biosynthesis machinery and suggest an avenue for therapeutic targeting of nonsense mutations using endogenous factors.